What is Insulin Patent Evergreening?
Insulin patent evergreening refers to a strategy where pharmaceutical companies obtain multiple patents on a drug, often for minor modifications or new formulations, after the original patent expires. This practice can extend the period of market exclusivity beyond the initial patent term, thereby delaying the entry of lower-cost generic or biosimilar versions [1].
How Does Insulin Patent Evergreening Work?
Companies may patent different insulin formulations, delivery devices, or methods of use for an existing insulin product. For example, a patent might be filed for a new pen device, a different concentration of insulin, or a combination therapy. While these might offer some therapeutic advantages, they can also serve to create new patent barriers that prevent competitors from marketing generic alternatives to the original product [2].
Why Are Companies Challenging Insulin Patents?
Patent challenges, particularly in the context of insulin, are driven by the desire to lower drug costs and increase patient access. Generic manufacturers and biosimilar developers often contest secondary patents that they believe do not represent genuine innovation but are instead tactics to extend a monopoly. The high cost of insulin in many markets has led to increased scrutiny of these patent strategies [1][2].
When Does Insulin Exclusivity Expire?
The expiration of exclusivity for insulin products depends on the specific patents held by the manufacturer. While the original patents for many older insulins have expired, newer formulations and delivery systems may have their own, more recent patent protections. DrugPatentWatch.com tracks patent expiry dates for various medications, including insulins, providing detailed timelines for when market exclusivity is expected to end for different patents [1].
What Are the Risks Associated with Insulin Evergreening?
The primary risk associated with insulin patent evergreening is the continued high cost of insulin for patients. By extending market exclusivity, these strategies can prevent competition from biosimilar insulins, which are typically offered at lower prices. This can lead to financial strain for patients, particularly those without adequate insurance, and may impact adherence to treatment [1][2].
Can Biosimilars Enter Before Patent Expiry?
Biosimilar entry typically occurs after the relevant patents expire and market exclusivity ends. However, the process can be complex due to the multiple patents that may cover different aspects of an insulin product. Legal challenges and patent litigation can sometimes delay the approval and market entry of biosimilars, even if some of the original patents have expired [2].
What Are the Alternatives to High-Cost Insulin?
Alternatives to high-cost insulin include seeking out biosimilar versions when available, exploring patient assistance programs offered by manufacturers, and advocating for policy changes that promote competition and reduce drug prices. For some individuals, exploring different types of insulins or treatment regimens might also be an option, although this should always be done under medical supervision [1][2].
Sources
1. https://drugpatentwatch.com/
2. Information on patent evergreening strategies and their impact on drug pricing.